The global neurological biomarkers market size was exhibited at USD 9.14 billion in 2024 and is anticipated to attain around USD 30.77 Billion By 2034, growing at a impressive CAGR of 12.90% from 2024 to 2034
Key Takeaways
- North America dominated the neurological biomarkers market with the largest market share of 40% in 2023.
- Asia Pacific is estimated to be the fastest-growing during the forecast period of 2024-2033.
- By type, the proteomic biomarkers segment dominated the market in 2023.
- By type, the other segments are anticipated to grow significantly during the forecast period.
- By application, the Alzheimer’s disease segment dominated the market in 2023.
- By application, the Parkinson’s disease segment is expected to grow substantially during the forecast period.
- By end-use, the research organizations & others segment dominated the neurological biomarkers market in 2023.
- By end-use, the hospital & hospital laboratories segment is estimated to be the fastest-growing during the forecast period.
Get the Sample Copy of This Report@ https://www.precedenceresearch.com/sample/5109
Market Overview
The Neurological Biomarkers Market focuses on the identification, measurement, and utilization of biomarkers related to neurological conditions. These biomarkers—biological indicators found in body fluids, tissues, or other body parts—help in diagnosing, predicting, and monitoring various neurological diseases. With an increase in neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, the demand for advanced diagnostic tools has risen significantly. Neurological biomarkers provide critical insights that aid in early diagnosis and effective treatment plans, improving patient outcomes and fostering advancements in personalized medicine.
Growth Factors
The market’s growth is driven by the rising prevalence of neurological disorders, which has amplified the need for early and accurate diagnosis. Advances in biomarker discovery techniques, including genomics, proteomics, and imaging, have expanded the scope of neurological biomarkers. Additionally, a surge in funding for neurological research, along with collaborations between research institutions and biotechnology firms, is contributing to market expansion. Increasing awareness about neurological conditions and a shift toward preventive healthcare are further fueling the demand for biomarker-based diagnostics.
Market Scope
| Report Coverage | Details |
| Market Size by 2034 | USD 30.77 Billion |
| Market Size in 2024 | USD 9.14 Billion |
| Market Growth Rate from 2024 to 2034 | CAGR of 12.90% |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2034 |
| Segments Covered | Type, Application, End-use, and Regions |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Market Dynamics
Drivers
Key drivers of the Neurological Biomarkers Market include technological advancements in biomarker detection and diagnostics, as well as increasing adoption of biomarkers in clinical trials. These biomarkers are essential for understanding disease mechanisms, identifying therapeutic targets, and improving drug efficacy, which is crucial for pharmaceutical companies. Regulatory support for biomarker development, coupled with the growing investment in biomarker research, is also driving the market. Furthermore, the aging population and associated increase in neurological disorders significantly boost demand for early diagnostic solutions.
Opportunities
There are substantial opportunities in the market for developing novel biomarkers that can detect neurological diseases at an asymptomatic stage, which would revolutionize early intervention and patient management. Expanding applications of biomarkers in personalized medicine and precision therapies also present significant growth potential. In addition, there is an increasing opportunity for partnerships between academic institutions, biotech firms, and pharmaceutical companies to expedite biomarker research. Emerging markets, such as Asia-Pacific and Latin America, represent untapped potential due to increasing healthcare expenditure and growing awareness of neurological disorders.
Challenges
Despite its promising growth, the Neurological Biomarkers Market faces several challenges, including high costs associated with biomarker discovery and validation. Regulatory complexities and the need for standardization in biomarker testing procedures can hinder market progress. Additionally, the inherent complexity of neurological disorders, which often involve multiple biomarkers, poses a challenge for researchers in identifying specific and reliable markers. Limited access to sophisticated diagnostic technologies, particularly in low- and middle-income regions, further restricts market expansion.
Region Insights
North America dominates the Neurological Biomarkers Market, owing to advanced healthcare infrastructure, substantial research funding, and a high prevalence of neurological disorders. Europe follows closely, with significant investments in neurological research and a strong emphasis on early diagnosis and personalized medicine. The Asia-Pacific region is expected to experience rapid growth, driven by rising healthcare spending, increased awareness of neurological diseases, and expanding access to diagnostic tools. Latin America and the Middle East & Africa are also emerging markets with growing healthcare infrastructures and a gradual increase in neurological research activities.
Read Also: Automotive Differential Market Size is Expanding USD 38.53 Billion by 2034
Recent Developments
- In April 2024, in New York, new research to identify biomarkers for cerebral amyloid angiopathy (CAA) and related CAA-related inflammation by comparing measures of BBB (blood-brain barrier) disruption and inflammation between 2 groups of patients was launched by Presbyterian and Weill Cornell Medicine neurologist, Samuel Bruce, MD.
- In May 2024, to develop a new TBI (traumatic brain injury) diagnostics, with an added focus on diagnosing mild TBI, Danaher announced they launched a collaboration with Johns Hopkins University. It helps to potentially initiate a correlation between a new biomarker panel and clinical outcomes.
Neurological Biomarkers Markets Top Companies
- Rules-Based Medicin
- Alseres Pharmaceuticals, Inc.
- Quanterix
- Banyan Biomarkers, Inc.
- DiaGenic ASA
- Johnson & Johnson Services, Inc.
- Bio-Rad Laboratories, Inc.
- Merck & Co., Inc
- Thermo Fischer Scientific, Inc.
- Abbott
- Olink Biosciences
- ACOBIOM
- Enrolmmun
- ADx NeuroSciences NV
- Qiagen
- PERKINELMER INC.
- F. Hoffman La-Roche Ltd.
- Shimadzu Corporation
- Neurobio
- Myriad RBM (Myriad Genetics, Inc.)
Segments Covered in the Report
By Type
- Genomic
- Proteomic
- Metabolomic
- Imaging
- Others
By Application
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Autism Spectrum Disorder
- Others
By End-use
- Hospital & Hospital Laboratories
- Independent clinical diagnostic centers
- Research Organizations & Others
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East & Africa
Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/5109
Contact Us:
Mr. Alex
Sales Manager
Call: + 1 804 441 9344
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.dailystatsnews.com/
Blog: https://www.dailytechbulletin.com/